Phase 1 Study of Tazemetostat, An Enhancer of Zeste Homolog-2 (EZH2) Inhibitor, In Pediatric Patients With Relapsed/Refractory Integrase Interactor 1 (INI1)-Negative Tumors

被引：0

作者：

Chi, S. ^{[1
]}

Bourdeaut, F. ^{[2
]}

Laetsch, T. ^{[3
]}

Fouladi, M. ^{[4
]}

Macy, M. ^{[5
]}

Makin, G. ^{[6
]}

Shukla, N. ^{[7
]}

Wetmore, C. ^{[8
]}

Margol, A. ^{[9
]}

Casanova, M. ^{[10
]}

Kilburn, L. ^{[11
]}

Yi, J. ^{[12
,13
]}

Hargrave, D. ^{[14
]}

Mccowage, G. ^{[15
]}

Pinto, N. ^{[16
]}

Ebb, D. ^{[17
]}

Robinson, G. ^{[18
]}

Sierra, L. ^{[19
]}

Merchant, M. ^{[19
]}

Nysom, K. ^{[20
]}

机构：

[1] Dana Farber Canc Inst, Neurooncol, Boston, MA 02115 USA

[2] Curie Inst, Care Innovat Res, Childhood Canc, Adolescents & Young Adults, Paris, France

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA

[4] Cincinnati Childrens Hosp, Canc & Blood Dis, Brain Tumor, Oncol, Cincinnati, OH USA

[5] Childrens Hosp Colorado, Canc & Blood Disorders, Expt Therapeut, Oncol, Aurora, CO USA

[6] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[7] Mem Sloan Kettering Canc Ctr, Pediat Hematol Oncol, 1275 York Ave, New York, NY 10021 USA

[8] Phoenix Childrens Hosp, Hematol & Oncol, Phoenix, AZ USA

[9] Childrens Hosp Los Angeles, Canc & Blood Dis Inst, Los Angeles, CA 90027 USA

[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[11] Childrens Natl Hosp, Brain Tumor Inst, Ctr Canc & Blood Disorders, Expt Therapeut Program,Oncol,Neurofibromatosis In, Washington, DC USA

[12] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Canc Ctr, Houston, TX 77030 USA

[13] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Hematol Ctr, Houston, TX 77030 USA

[14] Great Ormond St Hosp Sick Children, Dept Haematol & Oncol, London, England

[15] Childrens Hosp Westmead, Canc Ctr Children, Clin Trials, Westmead, NSW, Australia

[16] Seattle Childrens Hosp, Hematol Oncol, Seattle, WA USA

[17] Massachusetts Gen Hosp, Canc Care, Pediat, Boston, MA 02114 USA

[18] St Jude Childrens Res Hosp, Dept Oncol, St Jude Grad Sch Biomed Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[19] Epizyme, Early Stage Dev, Cambridge, MA USA

[20] Rigshosp, Paediat & Adolescent Med, Copenhagen, Denmark

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0261

引用

页码：S123 / S124

页数：2

共 50 条

[21] Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer
Chandnani, Nikhil
Gupta, Ishika
Thakkar, Vidhi
Sarkar, Koustav
PATHOLOGY RESEARCH AND PRACTICE, 2023, 251
[22] Enhancer of zeste homolog 2 (EZH2) expression in G1-G2 Pancreatic Neuroendocrine Tumor (pNET)
Marconcini, R.
Faviana, P.
Campani, D.
Galli, L.
Antonuzzo, A.
Falcone, A.
Ricci, S.
ANNALS OF ONCOLOGY, 2016, 27
[23] Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
Zauderer, Marjorie Glass
Szlosarek, Peter
Le Moulec, Sylvestre
Popat, Sanjay
Taylor, Paul
Planchard, David
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Pagel, John
Morschhauser, Franck
Herve, Tilly
Chaidos, Aristeidis
Phillips, Tycel
Ribrag, Vincent
Campbell, Phillip
Fruchart, Christophe
Jurczak, Wojciech
McKay, Pamela
Opat, Stephen
Radford, John
McDonald, Alice
Howell, Haley
Newberry, Kate
Woodruff, Mark
Clawson, Alicia
Larus, John
Blakemore, Stephen
Miao, Harry
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S278 - S279
[25] Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Kindler, H.
Harvey, R. D.
Duska, L. R.
Gandhi, L.
Sullivan, R. J.
Gastinne, T.
Kwiatek, M.
Garcia-Sancho, A. M.
Hadar, N.
Kann, L.
Faulhaber, N.
Drescher, C.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S31 - S32
[26] Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
Schweizer, Michael Thomas
Penkov, Konstantin
Choudhury, Atish Dipankar
Calvo, Emiliano
Frank, Richard C.
Liu, Li
Mittapalli, Rajendar K.
Tougias, Jessica
Andreu-Vieyra, Claudia
Bowler, Timothy Geoffrey
Soman, Neelesh
Garmezy, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma
Ribrag, V.
Soria, J. C.
Reyderman, L.
Chen, R.
Salazar, P.
Kumar, N.
Kuznetsov, G.
Keilhack, H.
Ottesen, L. H.
Italiano, A.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 197 - 197
[28] Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2
Maleszewska, Monika
Gjaltema, Rutger A. F.
Krenning, Guido
Harmsen, Martin C.
CELLULAR SIGNALLING, 2015, 27 (08) : 1589 - 1596
[29] Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T -Cell Leukemia/Lymphoma
Yoshimitsu, Makoto
Izutsu, Koji
Makita, Shinichi
Nosaka, Kisato
Utsunomiya, Atae
Kusumoto, Shigeru
Morishima, Satoko
Tsukasaki, Kunihiro
Kawamata, Toyotaka
Ono, Takaaki
Rai, Shinya
Katsuya, Hiroo
Ishikawa, Jun
Yamada, Hironori
Kato, Kazunobu
Tachibana, Masaya
Kakurai, Yasuyuki
Adachi, Nobuaki
Tobinai, Kensei
Yonekura, Kentaro
Ishitsuka, Kenji
BLOOD, 2021, 138
[30] Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Gounder, Mrinal
Schoffski, Patrick
Jones, Robin L.
Agulnik, Mark
Cote, Gregory M.
Villalobos, Victor M.
Attia, Steven
Chugh, Rashmi
Chen, Tom Wei-Wu
Johan, Thierry
Loggers, Elizabeth T.
Gupta, Abha
Italian, Antoine
Demetri, George D.
Ratan, Ravin
Davis, Lara E.
Mir, Olivier
Dileo, Palma
Van Tine, Brian A.
Pressey, Joseph G.
Lingaraj, Trupti
Rajarethinam, Anand
Sierra, Laura
Agarwal, Shefali
Stacchiotti, Silvia
LANCET ONCOLOGY, 2020, 21 (11): : 1423 - 1432

← 1 2 3 4 5 →